111 related articles for article (PubMed ID: 33662457)
1. Design and synthesis of a novel mitochondria-targeted osteosarcoma theranostic agent based on a PIM1 kinase inhibitor.
Yi X; Cao Z; Yuan Y; Li W; Cui X; Chen Z; Hu X; Yu A
J Control Release; 2021 Apr; 332():434-447. PubMed ID: 33662457
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biological significance of PIM1 kinase in osteosarcoma.
Liao Y; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
J Orthop Res; 2016 Jul; 34(7):1185-94. PubMed ID: 26687194
[TBL] [Abstract][Full Text] [Related]
3.
Alsubaie M; Matou-Nasri S; Aljedai A; Alaskar A; Al-Eidi H; Albabtain SA; Aldilaijan KE; Alsayegh M; Alabdulkareem IB
Oncol Lett; 2021 Aug; 22(2):622. PubMed ID: 34267815
[TBL] [Abstract][Full Text] [Related]
4. miR-486 inhibited osteosarcoma cells invasion and epithelial-mesenchymal transition by targeting PIM1.
Liu Y; Zhang J; Xing C; Wei S; Guo N; Wang Y
Cancer Biomark; 2018; 23(2):269-277. PubMed ID: 30103304
[TBL] [Abstract][Full Text] [Related]
5. Using insights into Pim1 structure to design new anticancer drugs.
Schenone S; Tintori C; Botta M
Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
[TBL] [Abstract][Full Text] [Related]
6. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
7. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
8. The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction.
Ye C; Zhang C; Huang H; Yang B; Xiao G; Kong D; Tian Q; Song Q; Song Y; Tan H; Wang Y; Zhou T; Zi X; Sun Y
Cell Physiol Biochem; 2018; 48(3):1230-1244. PubMed ID: 30045021
[TBL] [Abstract][Full Text] [Related]
9. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
Nakano H; Saito N; Parker L; Tada Y; Abe M; Tsuganezawa K; Yokoyama S; Tanaka A; Kojima H; Okabe T; Nagano T
J Med Chem; 2012 Jun; 55(11):5151-64. PubMed ID: 22540945
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis.
Remy J; Linder B; Weirauch U; Konovalova J; Marschalek R; Aigner A; Kögel D
Biochim Biophys Acta Mol Cell Res; 2019 Feb; 1866(2):175-189. PubMed ID: 30389373
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PIM1 kinase attenuates inflammation-induced pro-labour mediators in human foetal membranes in vitro.
Lim R; Barker G; Lappas M
Mol Hum Reprod; 2017 Jun; 23(6):428-440. PubMed ID: 28333279
[TBL] [Abstract][Full Text] [Related]
12. TAB3 upregulates PIM1 expression by directly activating the TAK1-STAT3 complex to promote colorectal cancer growth.
Li Q; Chen L; Luo C; ChenYan ; Ge J; Zhu Z; Wang K; Yu X; Lei J; Liu T; Peng X; Liu X; Yuan R
Exp Cell Res; 2020 Jun; 391(1):111975. PubMed ID: 32229191
[TBL] [Abstract][Full Text] [Related]
13. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.
Blanco FF; Jimbo M; Wulfkuhle J; Gallagher I; Deng J; Enyenihi L; Meisner-Kober N; Londin E; Rigoutsos I; Sawicki JA; Risbud MV; Witkiewicz AK; McCue PA; Jiang W; Rui H; Yeo CJ; Petricoin E; Winter JM; Brody JR
Oncogene; 2016 May; 35(19):2529-41. PubMed ID: 26387536
[TBL] [Abstract][Full Text] [Related]
14. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and immunomodulatory effects of PIM1 in colorectal carcinoma.
Zhou Y; Zhou Y; Liu S; Wang J; Ji R; Yan X
J BUON; 2021; 26(2):513-520. PubMed ID: 34077000
[TBL] [Abstract][Full Text] [Related]
16. PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway.
Cao L; Wang F; Li S; Wang X; Huang D; Jiang R
Cancer Lett; 2019 Mar; 444():116-126. PubMed ID: 30583073
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
18. 3D QSAR studies, molecular docking and ADMET evaluation, using thiazolidine derivatives as template to obtain new inhibitors of PIM1 kinase.
Aouidate A; Ghaleb A; Ghamali M; Ousaa A; Choukrad M; Sbai A; Bouachrine M; Lakhlifi T
Comput Biol Chem; 2018 Jun; 74():201-211. PubMed ID: 29635214
[TBL] [Abstract][Full Text] [Related]
19. PIM1 Promotes Survival of Cardiomyocytes by Upregulating c-Kit Protein Expression.
Ebeid DE; Firouzi F; Esquer CY; Navarrete JM; Wang BJ; Gude NA; Sussman MA
Cells; 2020 Aug; 9(9):. PubMed ID: 32878131
[TBL] [Abstract][Full Text] [Related]
20. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
